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ABSTRACT
Parkinson’s disease (PD) is the second most
common neurodegenerative disorder affecting mil-
lions of people. Both environmental and genetic fac-
tors play important roles in its causation and
development. Genetic analysis has shown that
over 100 genes are correlated with the etiology
and pathology of PD. However, accessing genetic
information in a consistent and fruitful way is not
an easy task. The Mutation Database for Parkin-
son’s Disease (MDPD) is designed to fulfill the
need for information integration so that users can
easily retrieve, inspect and enhance their knowledge
on PD. The database contains 2391 entries on 202
genes extracted from 576 publications and manually
examined by biomedical researchers. Each genetic
substitution and the resulting impact are clearly
labelled and linked to its primary reference. Every
reported gene has a summary page that provides
information on the variation impact, mutation type,
the studied population, mutation position and refer-
ence collection. In addition, MDPD provides a
unique functionality for users to compare the differ-
ences on the type of mutations among ethnic
groups. As such, we hope that MDPD will serve as
a valuable tool to bridge the gap between genetic
analysis and clinical practice. MDPD is publicly
accessible at http://datam.i2r.a-star.edu.sg/mdpd/.
INTRODUCTION
Parkinson’s disease (PD) is a progressive neurological dis-
ease that aﬀects millions of people world wide, with
 1.8% of the population at age >65 years (1). The
death of dopaminergic neurons in the substantia nigra is
a pathological feature of the disease. PD is a complicate
disease that both environmental and genetic factors
play various roles in its causation and development.
The genetic evidence is that ﬁrst degree relatives of the
familial PD patients are more vulnerable to PD than the
general population, especially signiﬁcant for early-onset
PD (2,3). However, reliable biomarkers or tests to facil-
itate early and accurate diagnosis are currently not avail-
able (4). Genetic testing, if available, could complement
clinical diagnostic criteria. Several genetic mutations and
variants (point substitution, deletion, insertion or even
polymorphisms) have been positively associated with PD
(5,6). PARK2, LRRK2, PINK1, SNCA, UCHL1 and
PARK7 are the most frequently studied genes (7). Some
of the genetic variants are considered as causal factors
while others may cause neuronal dysfunction indirectly.
For example, mutations in the 50-UTR of NR4A2 have
signiﬁcantly decreased the expression of NR4A2 gene and
its downstream gene tyrosine hydroxylase (8). At present,
over 100 genes have been reported to associate with PD in
various forms. Some of these genetic variants are wide-
spread in patients while others are ethnic-related risk
factor. LRRK2 G2019S is a common pathogenic muta-
tion found in 5–7% of familial PD and 1–2% of sporadic
PD worldwide (9,10). At the same time, this mutation
shows speciﬁc ethnic prevalence with exceptionally high
frequency in North African Arabs (37–42% in familial
and 41% in sporadic PD) (11) but is rare in Chinese
(12,13). Another population-speciﬁc example is the GBA
gene mutation. Both R496H and c.84insGGfs are found in
patients from Ashkenazi Jews (14,15) and have not been
reported in other ethnic groups. Genetic screening and
treatment strategies could be improved if genetic features
have been well characterized. Further elucidation of such
information may also lead to new developments in diag-
nostic methods and early treatment.
Due to advances in genetic technology and the polygenic
nature of PD, genetic information of the disease has accu-
mulated rapidly in the past decade. The amount of data is a
daunting challenge for individual researchers in searching
and examining desirable information. For instance, there
are over 1300 reports in the PubMed database if
‘Parkinson’s disease’ AND ‘mutation’ are the keywords
of search. The combination of gene names, oﬃcial symbols
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culty of retrieving relevant information. In addition,
although information of gene function, gene sequences,
protein structure and mutation reports are searchable,
their availability are scattered across various databases
such as Entrez Gene (16), GenBank (17), Swiss-Prot (18),
OMIM (19) and PubMed (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=PubMed). The Human Gene Mutation
Database [HGMD; (20)], which covers mutation informa-
tion for over 2800 human genes, is the most comprehensive
but its public free-access version is limited to less-updated
information. Moreover, it is not built speciﬁcally for PD. If
one searches the HGMD for PD, one may only get the
mutation information for less than 20 genes. Thus, to
obtain desired information, researchers have to perform
at least two time-consuming tasks: (i) examine large
volume of data; and (ii) query a number of diﬀerent data-
bases.ThereareafewdatabasesthatspecializeinPDmuta-
tion information, but they are limited in either coverage or
functionality. For example, the LOVD Parkinson’s disease
mutation database developed by the Parkinson’s Institute
in Leiden University (http://www.grenada.lumc.nl/
LOVD2/TPI/home.php) brieﬂy covers six genes with
total of 71 variants. The PDGENE (http://www.pdgene.
org/) is more comprehensive and contains the most
updatedlistofPDcandidategeneswithemphasisingenetic
association studies. However, it lacks the functionality for
ethnic comparison and it does not provide summary and
statistic reports. To address some of the current limitations
of PD databases and to facilitate eﬀective and comprehen-
sive information acquisition, we have developed the
Mutation Database for PD (MDPD). Through a single
online location with user-friendly interfaces, researchers
are able to retrieve the latest information on PD, covering
genetic variation (mutation and polymorphism), popula-
tion studies, literature evidence and gene sequences.
Various cross-references to public databases are incorpo-
rated to assist further exploration and evaluation.
DATA SOURCE AND CLASSIFICATION
MDPD is a specialist database that presents the human
mutation information relevant to PD as an online
resource. Data from animal models and cell lines are not
included. Mutation evidences are extracted from PubMed
database (from 1995 to 10 June 2008) based on keyword
search [‘Parkinson’s disease/genetics’ (MeSH)]. Sequences,
variants and general gene information are obtained from
other databanks as mentioned above (the latest update of
MDPD was 4 September 2008). Every mutation entry has
been manually examined by a researcher specialized in
genetics. Important information, such as size of study
sample, control group, population, age of onset, type of
PD (sporadic versus familial), mutation outcome, its refer-
ence sequence and possible impact of the variant, have
been manually extracted from the data source.
In addition to mutation, single nucleotide polymor-
phism (SNP) shows the linkage between genotype and
the susceptibility of disease (21). SNPs can fall within
the coding region and non-coding region in most cases.
In non-coding region, a SNP does not change protein
sequence but may still have consequences on the risk of
disease by aﬀecting the splicing site or transcription factor
binding site. Some SNPs have protective eﬀects while
others may increase the risk of PD, or show no signiﬁcant
outcomes and need further research. As we believe SNP
information plays an important role in the design of
genetic tests and also in understanding the mechanisms
of the disease, they are included in our database. On the
other hand, variations that lack precise genetic locations,
such as variants in approximate chromosome regions or
markers in inter-gene regions, are not included in MDPD.
We believe genetic location is very critical in mutation
study and such approximate results need to be resolved
before inclusion in the database.
Case–control studies and genome-wide association stu-
dies (GWAS) have shown that PD is a polygenic disease
that multiple gene mutations are responsible for the mal-
function(7,22).EvenmonogeneticcausesofPDcouldhave
resulted from a variety of mutations. The mutations in a
particular gene can yield diverse consequences. A single
nucleicacidsubstitutionmayleadtoamultitudeofpossible
outcomes, including amino acid exchange (missense muta-
tion),noaminoacidchange(silentmutation), peptidetrun-
cation (nonsense mutation), absence of the protein
(deletion) and even the production of a diﬀerent protein
(frame shift or insertion). Other types of mutation, such
as duplication and compound mutation (more than one
type of mutation) are also found in PD. As such, we cate-
gorize the genetic variations into the following: missense
mutation, silent mutation, nonsense mutation, compound
mutation, deletion, insertion, duplication, triplication,
frame shift, short repeat and SNP. All of these classiﬁca-
tions are based on the primary reference as the trusted data
resource. We believe that such categorization can help the
user to examine and compare the variations more eﬃ-
ciently. Another classiﬁcation in MDPD is the variations’
impact to reﬂect the outcomes of the variations. Divergent
impacts are expected due to diﬀerences in the method used,
sample size and the studied population. One variation may
have more than one ‘Impact’. For example, the V380L
substitution in PARK2 gene is marked ‘Associated’ since
it has been found in the sample of early onset PD patient
(23). It is also tagged as ‘Negative Result’ in other occasion
due to the lack of signiﬁcant association with patients (24).
Such inevitable discrepancy of impact reﬂects the compli-
cated nature of PD in which multiple genetic factors
play various roles and that interactions between genetic
and environmental factors may inﬂuence the end result
dynamically. According to the found eﬀects of each varia-
tion, we classiﬁed its ‘Impact’ as ‘protective factor’, ‘risk
factor’, ‘associated’, ‘questionable’ and ‘negative result’.
For example, if ‘protective’ or ‘risk’ eﬀect has been men-
tioned in the primary reference of a variance, we assign its
impact as ‘protective factor’ or ‘risk factor’. ‘Associated’ is
allocated to variances showing signiﬁcant diﬀerence
between patients and controls. If a variance has
been reported in both patients and controls without statis-
tic diﬀerence, we label it as ‘questionable’. The classiﬁca-
tion aims to help user recapitulate information according
to comparison outcome.
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MDPD is designed to be a publicly accessible online
resource with user-friendly interface. MySQL, a reliable
and proven relational database, is used to organize infor-
mation. A web-based user interface to the database is
provided via an Apache 2.0 HTTP server with PHP script-
ing engine.
MDPD contains the following functional pages:
Browser, Search, Compare, Statistics and Variation
Report. Three searching options are available in the
search page: a variation search can be based on the gene
name, gene ID or SWISS-PROT accession number. In
accordance to the recommendations from the HUGO
Nomenclature Committee, oﬃcial gene symbols are used
in each record, but MDPD also provides all known aliases
in the result pages for easy reference and retrieval. For
example, both PARK1 and SNCA are valid search
terms in the database. Searching mutation information
based on geographic region or the author’s name in refer-
ence collection are two other helpful options. Searching
for mutation information based on a geographic region
enables a user to quickly know what genes have been
studied in the region (or population) and the number of
related publications may indicate regional research eﬀorts.
On the other hand, searching for mutation information
based on the reference author’s name can help researchers
in the community easily identify various leading authors’
research interests and their collaborators. Hyperlinks to
each reference and gene symbol are provided in the
report page.
Various useful features have been built into MDPD and
span several web pages for ease of use and navigation. The
complete list of web pages and their corresponding features
are listed in Table 1. We highlight the ‘Variation Report’
page here as we believe that it is a useful feature of MDPD.
In addition to providing the generic gene information,
hyperlinks to Entrez, Swissport and OMIM, the
‘Variation Report’ page also covers detailed information
of ‘Variation Impact’, ‘Variation Type’, ‘Studied coun-
tries’, ‘Variation sequence’ (in both amino acid and nucleic
acid levels) and ‘PubMed collection’. For ‘Variation
Impact’ and ‘Variation Type’, we do not attempt to
modify the ﬁndings from the primary reference, as we
have mentioned previously. Users are advised to judge
the classiﬁcation based on his/her knowledge and the
up-to-date research. To understand the impact of a genetic
substitution, the user should be aware of any conﬂicting
results from divergent ethnic groups or from speciﬁc sub-
sets of patients. Such information is readily accessible in
MDPD. ‘Studied countries’ provides information about
the geographic regions and ethnic groups of patients stu-
died. This information is also valuable for reﬁning popula-
tion screening target to avoid wasting resource.
Researchers may also use it to identify key genetic factors,
namely those for which impactful variations have been
reported in many geographic regions (or ethnic groups).
For example, MDPD includes 74 literature reports that
described 258 diﬀerent variants of PARK2 from 33 geo-
graphic regions. Deletion, duplication, triplication, inser-
tion, missense mutation, nonsense mutation, silent
mutation and compound mutations were all found in this
gene. Among them, missense mutation and deletion are the
most frequently conveyed with 140 and 86 records, respec-
tively. Based on such information, a user can make reason-
able inference about the importance of PARK2 instantly.
To further conﬁrm his/her speculation, the user can exam-
ine the primary reference through ‘PubMed collection’ and
investigate the mutation ‘hot sport’ through ‘Variation
sequence’.
Allowing users to compare mutations between ethnic
groups is another helpful element of MDPD. Users can
readily obtain a list of mutation genes of an interested
ethnic group from ‘Search’. Comparing the mutations
between two ethnic groups of interest can also be done
easily in ‘Comparison’. Currently, more than 2300 entries
covering 202 human genes are stored in MDPD. Through
systematic data mining on the integrated information,
MDPD oﬀers researchers new means for inspecting and
making sense of the mutation evidences in published
ﬁndings.
MDPD is publically accessible at http://datam.i2r.
a-star.edu.sg/mdpd/.
DISCUSSION
Gene mutations and variations have become the focus of
PD research in the last decade. Linkage mapping, case–
control study, pedigree analysis and GWAS are powerful
approaches to identify and correlate genetic contribution
Table 1. Functional summary of MDPD
Web page Contents
Browse Alphabetic list of gene symbol
Chromosomal location of the gene
Links to Entrez Gene and SWISS-PROT databases
Entry to summary page
Search Search gene name, symbol, aliases (allow partial
name), gene ID, SWISS-PROT ID
Search studied geographic regions (ethnic group)
Search author’s name for primary reference
Summary About the gene
Number of records for the gene
Number of variants reported in SWISS-PROT
database
Link to OMIM database
Number of Pubmed reference for the gene in
MDPD
Variation report List of variation impact
List of variation type
List of studied geographic regions (ethnic groups)
Variation sequence (in both amino acid and
nucleic acid levels)
List of PubMed reference for the gene
Entry to individual variation report (sample size,
control group, age, gender, testing variation,
impact, geographic and comments)
Comparison Comparing genetic data from any two
geographic regions
Statistics Key statistics in MDPD
Top 10 genes with most literature reports
Top 10 genes with most reported negative variants
Top 10 countries/regions with most studies done
D860 Nucleic Acids Research, 2009, Vol. 37, Databaseissueto PD. However, how various mutations and variants
aﬀect the disease and shape its development remains
unclear. In addition, each mentioned approach has certain
limitations. Various research biases and errors contribute
to fewer reproducible association ﬁndings and diminish
the assessing power between genetic variants and the
risk of common disease (25,26). To partially overcome
the limitation of accumulated imperfect data, we intend
to include all published literatures with precise number of
sample size (both case and control), variation position,
variation impact and geographic location. We expect mul-
tiple independent genetic studies could yield meaningful
results. At the same time, we remind users to be caution
in interpretation of deductions from published data.
Many genes and multiple variants in a gene are regis-
tered positive correlation with PD. Possessing the avail-
able information is an essential ﬁrst step to further
understand and eventually to elaborate eﬀective strategies
for diagnosis and treatment. MDPD is an integrated infor-
mation system that aims to facilitate PD research. It con-
tains records for over 100 PD-associated genes veriﬁed
from various genetic tests. Among them, the top 10
most reported mutation genes are LRRK2, PARK2,
SNCA, CYP2D6, MAPT, PINK1, UCHL1, PARK7,
MAOB and APOE (Table 2). The data in MDPD also
reveal that current research has been focused in certain
key genetic targets—the top 10 genes accounted for 1053
entries from 326 publications, which makes up to 44% of
the total records and more than half of the literature
reports (57%) in MDPD. At the same time, we realize
that 202 genes are somewhat under the current research
radar.
Another interesting outcome from MDPD is the high
frequency of ‘negative result’ in the variation reports. For
example, >30% of records are labelled ‘negative’ in 9 out
of the top 10 most reported genes (the exception is
PARK2 with 15.2% negative reports). There are at least
three implications: (i) many variants have low incident
rates in PD patients and may not be a good screening
target for survey; (ii) these variants may have insigniﬁcant
impact to PD; and (iii) discrepancy may be caused by
ethnic-related genetic variance, sample size, methods
used or research errors. The variants with the most posi-
tive reports could be valuable genetic targets and further
studies on them may warrant potential breakthrough in
diagnosis and treatment.
PD is a multi-factorial disease for which the environ-
mental factors and genetic elements are likely to be equally
important. Studies have showed that lifestyles (such as
smoking and coﬀee consumption), pesticides and metal
exposure, and even well water drinking are factors that
inﬂuence the risk of disease in both sporadic and early-
onset PD (27,28,29). The involvement of multiple genes,
the high incident rate in aging population and high per-
centage of sporadic cases suggest the possibility of multi-
ple interactions and connections in etiology of PD. In
many cases, it is diﬃcult to isolate the environmental fac-
tors and to specify the short- and long-term exposure. As
such, we did not include environmental study information
in MDPD, but the user should be mindful about the
potential interactions with environmental factors.
FUTURE WORK
Discovering the relationships between the various genetic
factors is an essential step toward understanding the
mechanism of complex diseases such as PD. From
MDPD, we know at least 202 genes have been examined
for their possible involvement in PD. Our future work
would be to develop an information system that can
assess the impact of disease-causing mutations in terms
of the functional changes of their encoded proteins and
the interactions. Further integrated information, such as
multiple level protein–protein interactions, and the role of
the genetic variants in various neurodegenerative path-
ways will hopefully provide insights that will lead to
novel treatments for PD.
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